Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATX-Red (also known as AR-2) is an in vivo near-infrared (NIR) fluorogenic imaging probe developed by Echelon Biosciences for visualizing and measuring autotaxin (ATX, also known as ENPP2) activity. Chemically, ATX-Red is an analog of lysophosphatidylcholine (LPC), the natural substrate of autotaxin, and is conjugated to a near-infrared fluorophore (Licor IRDye 800CW) and a quencher (Licor IRDye QC-1). In its intact state, the fluorescence of ATX-Red is quenched via intramolecular energy transfer. Upon cleavage of the choline-like head group by the lysophospholipase D (lysoPLD) activity of autotaxin, the fluorophore is released from the quencher, resulting in a significant increase in near-infrared fluorescence. This probe is primarily used as a research tool in animal models to monitor tumor progression, evaluate the efficacy of autotaxin inhibitors, and study diseases associated with dysregulation of the ATX/LPA pathway, such as metastatic cancers, idiopathic pulmonary fibrosis, and rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ATX-Red.